From the Division of Cardiology, Emory University School of Medicine,
Atlanta, Ga.
Correspondence to Zorina S. Galis, PhD, Emory University School of Medicine, Division of Cardiology, 1639 Pierce Dr, WMB #319, Atlanta, GA 30322. E-mail zgalis{at}emory.edu
Methods and ResultsWe used a
hypercholesterolemic rabbit model of
atherosclerosis to investigate the
gelatinolytic activity associated with
macrophage-derived foam cells (FCs).
Gelatinolytic activity and expression of MMP-9 but
not of MMP-2 cosegregated with macrophage FCs in aortic
lesions. Macrophage-derived gelatinases were further
investigated in vitro. MMP-9 was identified as the main
macrophage-derived gelatinase in cells isolated from aortic
lesions and from granuloma induced in the same rabbits to increase cell
yield. Importantly, detection of activated MMP-9 in the FC
culture medium supports the notion that these cells can independently
initiate processing of secreted MMP zymogens to active enzymes. We
further examined whether FC gelatinolytic activity
is dependent on the presence of reactive oxygen species (ROS). We found
that treatment (1 to 5 days) with 1 to 10 mmol/L
N-acetyl-L-cysteine (NAC), an ROS scavenger,
decreased not only gelatinolytic activity but also
gelatinase expression by FCs. Similarly, NAC treatment of explanted
lesions abolished in situ gelatinolytic activity
and MMP-9 expression.
ConclusionsMacrophage FCs are an abundant source of
gelatinolytic activity that can be inhibited in
vitro and in situ by NAC. This newly described action of antioxidant
therapy might prove useful to inhibit matrix degradation and to improve
vascular stability.
Isolation of Macrophages
Cell Culture Experiments
In Situ Treatment With ROS Scavengers
SDS-PAGE Zymography
Western Blotting
Histological Characterization of Aortic Tissue and
Isolated Cells
In Situ Zymography
Characterization of Lipid-Laden Macrophages
Macrophage-Derived FCs Release and Activate MMP-9
Effect of NAC on Protein Expression and Activity of
Macrophage-Derived MMP-9
NAC Reduces the Gelatinolytic Activity and In
Situ Expression of MMP-9 in Experimental Atherosclerotic
Lesions
Observations made on isolated macrophages in culture showed the
presence of active gelatinase, although all MMPs known so far are
reportedly secreted by cells as zymogens only. This in vitro
observation supports the notion that MMP-9 activation can occur
independently of the classic plasmin-mediated
pathway.12 The possibility that
macrophage gelatinolytic activity is
redox-dependent is suggested by our previous studies showing activation
of gelatinase zymogens by ROSs know to be produced by
macrophage FCs,13 as well as by our
present detection of active MMP-9 in an isolated cell system along
with inhibition of macrophage-derived
gelatinolytic activity by treatment with NAC, an
ROS scavenger. Activated macrophages, especially those
of atherosclerotic lesions, are a major source of ROSs; thus, such an
activation mechanism would result in activation of MMP zymogens
secreted by the macrophages themselves as well as by the
neighboring cells. However, our observations do not exclude the
possibility that activation of MMP-9 might occur through other
cell-dependent mechanisms, including the action of a group of cell
membrane molecules called MT-MMPs. It was reported that these molecules
activate the zymogens of MMP-2 and
MMP-13,31 but it is not yet known whether
monocytes/macrophages express MT-MMPs and whether proMMP-9,
the gelatinase whose activity was investigated in this study, is a
substrate for MT-MMPs.
NAC is widely used as an antioxidant on the basis of its capacity to
scavenge ROSs32; however, its
inhibitory effect on gelatinolytic
activity might also involve a direct interaction with the enzyme.
Although further biochemical studies will be necessary to differentiate
between these two possible components of gelatinase inhibition, the
capacity of NAC to inhibit gelatinolysis that we found is
unquestionable. This is important because regulation of
gelatinolytic activity ultimately determines the
level of matrix degradation by vascular gelatinases. However, our
results suggesting that NAC may also affect prior events in the pathway
leading to secretion of MMP-9 are also interesting. For instance, we
found that NAC treatment effectively inhibited the level of MMP-9
protein secreted in culture by macrophages. Findings from in
situ observations of macrophage-derived FCs of NAC-treated
experimental atheroma support NAC inhibition of MMP-9
expression. The hypothesis that redox stress modulates cellular MMP-9
expression is novel; thus, at present, the mechanism is still
unknown. Possibly relevant information is provided by studies showing
MMP-9 induction by cytokines and phorbol esters in a variety of
cells, including vascular endothelial cells and
SMCs.5 6 MMP-9 induction may require cooperation
between AP-1, NF-
Beneficial cardiovascular effects of various
antioxidant therapies were reported in human and experimental
atherosclerosis or restenosis, and efforts to
understand its mechanism of action are under
way.37 Treatments with probucol and vitamins E
and C38 39 40 have been shown to reduce intimal
lesions after balloon injury in hypercholesterolemic
animals. In addition to decreasing the lipid content and lesion area,
antioxidants also appear to alter lesion cellularity, reducing
primarily the monocyte-macrophage
content.41 In addition to potentially reducing
the extracellular effects of ROSs (eg, oxidative modification of
lipoproteins and activation of MMPs), scavenging ROSs may prevent or
diminish intracellular activation of redox-sensitive genes. Recently
published results showed that after dietary supplementation with
Received January 13, 1998;
revision received April 13, 1998;
accepted April 22, 1998.
© 1998 American Heart Association, Inc.
Basic Science Reports
N-Acetyl-Cysteine Decreases the Matrix-Degrading Capacity of Macrophage-Derived Foam Cells
New Target for Antioxidant Therapy?
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
BackgroundAtherosclerotic plaque
destabilization triggers clinical cardiovascular
disease and thus represents an attractive therapeutic target.
Weakening of tissue through the action of matrix-degrading enzymes,
called matrix metalloproteinases (MMPs), released by resident
macrophages was previously implicated in unstable vascular
syndromes.
Key Words: atherosclerosis metalloproteinases free radicals antioxidants
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
Macrophage-derived
FCs, which figure prominently in areas of atherosclerotic plaques prone
to rupture, are a likely source of plaque
instability.1 2 3 Many recent studies focusing on
various aspects of the active macrophage FC involvement in the
weakening of the vascular matrix scaffold suggest that it is a major
factor determining plaque vulnerability. Activated
macrophages release cytokines, which increase the
repertoire of matrix-degrading enzymes, called MMPs, secreted in vitro
by vascular cells4 5 6 and produce their own
MMPs.7 Furthermore, we and others have shown that
macrophage-derived FCs resident in human and experimental
atherosclerotic lesions are also associated with matrix-degrading
activity due to active MMPs.8 9 10 11 To digest
matrix components, however, latent cell-secreted MMPs require
posttranslational processing to active forms, a step acting as a key
regulatory mechanism of matrix degradation by
MMPs.12 In our search for MMP activation
mechanisms relevant to atherosclerosis, we recently
found that ROSs can trigger activation of MMP precursors released by
vascular SMCs.13 Similar ROSs are produced by
macrophage-derived FCs; thus, in addition to modulating
vascular MMP gene transcription via release of stimulatory cytokines, these cells may
regulate MMP enzymatic activation via release of ROSs. In addition,
macrophage-derived FCs most likely contribute with their
own MMPs to matrix degradation. Certain conditions enhance
production of MMPs by monocytic cells and cell
lines,7 and the intracellular lipid accumulation
characteristic of monocyte-derived macrophages residing in
atheroma could be one of them.14 We
found previously that the macrophage-derived FCs isolated
from aortic lesions of hypercholesterolemic rabbits
secrete in vitro precursors of the inducible MMPs
interstitial collagenase and
stromelysin.14 However, we did not detect
generation of their active forms, the only ones capable of matrix
degradation. We also did not investigate the expression of the
macrophage-derived gelatinases MMP-9 and MMP-2. These MMPs,
specialized in digestion of basement membrane collagens and
elastin,15 have since been implicated in
weakening of vascular tissue in unstable coronary
syndromes10 and in aortic
aneurysms.16 Thus, in the present
study, we sought to characterize gelatinase production by in
vivo differentiated macrophage FCs, which to the best of our
knowledge has not yet been investigated. We also explored the
hypothesis that gelatinase activity in atheroma areas rich
in macrophage-derived FCs is ROS-dependent and thus
inhibitable by ROS scavengers. For this purpose, we used an
experimental hypercholesterolemic rabbit model that
develops macrophage FCrich aortic lesions and allows
isolation of in vivo differentiated macrophage FCs for in vitro
studies.
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Animal Model of Atherosclerosis
Experimental atherosclerotic lesions were induced in the
double-injury rabbit model, in which aortic intimal lesions are rich in
lipid-laden macrophages.17 We induced
aortic lesions in New Zealand White rabbits (n=8), as previously
described in detail,14 by balloon angioplasty 1
week after initiating a hypercholesterolemic diet
(0.5% cholesterol and 4.5% coconut oil added to Purina
chow). The diet was maintained for the following 8 weeks. Three weeks
before the animals were killed, subcutaneous granulomas were induced in
the same rabbits by implantation of 2 or 3 sterile polyurethane sponges
(Baxter Scientific) per animal under the dorsal skin. A similar
procedure was used simultaneously to induce subcutaneous
granuloma formation in normocholesterolemic New Zealand
White rabbits on regular Purina chow. All animals were euthanized with
100 mg/mL pentobarbital. Aortas were harvested for morphological
processing, biochemical analysis, and isolation of FCs. Sponges
were removed under sterile conditions and used for isolation of
macrophages. The protocol for animal use was approved by the
Emory University Committee on Institutional Animal Care and Use.
Aortic lipid-laden macrophages were isolated from rabbit
atheromas as described previously.14
The aortic intima was separated and minced in ice-cold sterile HBSS.
Tissue was incubated with agitation at 37°C in sterile HBSS
containing collagenase (type I, Worthington), elastase,
and soybean trypsin inhibitor (Sigma Chemical Co), then
filtered through sterile nylon mesh. Granuloma macrophages were
collected by gentle squeezing of sponges. Macrophages were
further isolated by metrizamide-density centrifugation
as previously described and plated in Opti-MEM (Gibco-BRL).
Macrophage purity was assessed by immunocytochemical staining
as described below.
Macrophages and macrophage-derived FCs were
maintained in culture in serum-free Opti-MEM for up to 5 days. In some
experiments, NAC (100 µmol/L to 10 mmol/L) was added to the
culture medium of granulomatous macrophages. We harvested
cell-conditioned culture media and cell lysates obtained by use of
ice-cold 10 mmol/L phosphate buffer/150 mmol/L sodium
chloride containing 1% Triton X-100, 0.1% SDS, 0.5% sodium
deoxycholate, and 0.2% sodium azide. Cell viability was assessed at
the end of various treatments by the "Live-dead"
fluorescent kit (Molecular Probes). Computer-assisted image
analysis was performed with ImagePro Plus 2.0 software (Media
Cybernetics).
Paired aortic rings (of abdominal, thoracic, or aortic arch)
were incubated with or without 10 mmol/L NAC for up to 4 days.
Tissues were then processed for immunocytochemistry or extracted with
the lysis buffer and analyzed for
gelatinolytic activity by SDS-PAGE as previously
described.6 Conditioned culture media were
harvested and compared for expression and activity of secreted
gelatinases.
In this method, a gelatin substrate was included in the
composition of the polyacrylamide/SDS gels, and samples were
separated according to their apparent molecular weight by
electrophoresis. Areas of lysis appeared as white after renaturing and
staining of gels with colloidal Brilliant Blue G-250 (Fisher
Scientific). MMPs with gelatinolytic activity were
identified and compared in samples of culture media harvested from
explanted lesions or cultured macrophages. An increase in the
intensity of gelatinolytic bands with lower
apparent molecular weight and/or generation of new
gelatinolytic bands relative to bands
representing the zymogens is interpreted as gelatinase
activation.18 Gelatinolytic
bands were quantified after scanning densitometry with NIH Image 1.57
software. Statistical significance was investigated by Student's
t test with one-tailed distribution by use of Microsoft
Excel 5.0 software.
Culture media were separated on 10% SDS-PAGE minigels and
transferred onto nitrocellulose (Bio-Rad Laboratories). Incubation with
antiMMP-2 or antiMMP-9 monoclonal antibodies (Oncogene Science),
recognizing both the latent and active forms, was followed by
incubation with secondary antibodies coupled to horseradish peroxidase
and development of a chemiluminescent reaction (ECL kit from Amersham
International). Signals (positive bands) were quantified and
analyzed as described above.
Immunostaining was performed on frozen tissue
specimens embedded in O.C.T. compound (Miles) to identify
macrophages (antiRAM-11, Dako Corp) and to detect MMP-9 and
MMP-2 (Oncogene). Staining was developed with the LSAB staining kit
(Dako), and sections were counterstained with Gill's hematoxylin
(Sigma). Isolated cells were stained by single or double
immunofluorescence using species-specific secondary
antibodies coupled to fluorochromes (FITC or Texas Red, Jackson
ImmunoResearch). Nuclei were counterstained for 2 minutes with 0.5
µg/mL bisbenzamide (Calbiochem). Intracellular lipid accumulation was
revealed by staining of cells with 5 µg/mL Nile red (Molecular
Probes).
In situ gelatinolytic activity was detected
in frozen aortic tissue specimens as previously
described,9 with gelatin coupled to a green
fluorochrome. Briefly, tissues were processed for obtaining unfixed
frozen sections, which were placed on microscope slides previously
coated with fluorescent gelatin. The specimens were then
incubated at 37°C for 2 days and examined with a Zeiss
fluorescence microscope to reveal areas of active lysis of the
gelatin substrate.
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Gelatinolytic Activity Is Associated With
Increased MMP-9 Expression and Macrophage-Derived FCs in
Experimental Atheroma
Neointimal lesions developed in the double-injury
model of atherosclerosis were composed predominantly of
macrophage-derived FCs (Figure 1
) identified by immunohistochemistry
with a macrophage-specific antibody. The
gelatinolytic activity, examined by in situ
zymography, was restricted to the macrophage-rich intimal area.
Immunostaining for the two possible sources of
gelatinolytic activity, MMP-2 (gelatinase A) and
MMP-9 (gelatinase B), showed that expression of MMP-9 was specifically
associated with the neointimal lesion, whereas MMP-2
staining was diffuse. This observation suggested that the
macrophage-derived gelatinolytic
activity was due mainly to the presence of
macrophage-derived MMP-9.

View larger version (88K):
[in a new window]
Figure 1. Experimental atheroma in aorta of
hypercholesterolemic rabbits. Detection of
macrophages, gelatinolytic activity, and
expression of gelatinases MMP-2 and MMP-9. Top four panels illustrate
consecutive sections of lesions in abdominal aorta; bottom four panels,
in thoracic aorta. Top, Staining with cell-specific antibody (RAM-11)
identifies numerous macrophages in intimal region. Same region
contains gelatinolytic activity, as shown by
processing of a consecutive section by in situ zymography
(gelatinolytic activity is indicated by
disappearance of green fluorescent gelatin substrate used to
coat microscope slide). Immunostaining for MMP-2 and
MMP-9 gelatinases shows colocalization of macrophage
accumulations with MMP-9 expression but not with MMP-2. Bottom,
Macrophages, MMP-9 expression, and
gelatinolytic activity colocalize in a thoracic
aorta lesion. Control specimens were processed without primary antibody
(Ab). Bars=100 µm.
Further experiments were performed to confirm that the lipid-laden
macrophage was the source of MMP-9 and
gelatinolytic activity. However, to further
investigate expression and activation of gelatinases in culture, we had
to find an alternative source of macrophage-derived FCs,
the yield of aortic FCs being very limited
(3x105 to 106 cells per
aorta). We therefore produced and isolated in vivo differentiated
macrophage-derived FCs from subcutaneous granulomas of
hypercholesterolemic rabbits. To be able to assess
possible differences associated with the FC phenotype, we also
produced and studied, in parallel, nonlipid-laden macrophages
by implanting subcutaneous sponges in
normocholesterolemic rabbits. Isolated cells were
positively identified as being of macrophage origin by
immunofluorescence with the RAM-11 antibody (Figure 2
) and were used for the in vitro
experiments. Macrophage purity and viability were >98%. Nile
red staining confirmed intracellular lipid accumulation in
macrophages from hypercholesterolemic rabbits.
Granuloma FC yield was an order of magnitude higher than aorta
(2x107 to 3x107 per
rabbit). These FCs produced MMP-3 (Figure 2
), similar to
macrophage-derived FCs isolated from aortic
lesions.14

View larger version (72K):
[in a new window]
Figure 2. Macrophage-derived FCs isolated from
subcutaneous granuloma. Top, Cells isolated from subcutaneous granuloma
of hypercholesterolemic rabbits are identified by
immunofluorescence as macrophages (RAM-11
antibody). Inset, Negative control for immunostaining
in which primary antibody (Ab) was eliminated. Middle, Intracellular
lipid in macrophages from hypercholesterolemic
rabbits is revealed by staining with Nile red. Inset, Nile red staining
of macrophages (M
) from normocholesterolemic
rabbits. Bottom, Macrophage-derived FCs of granuloma
express stromelysin (MMP-3). Nuclei are counterstained with
bisbenzamide. Magnification x400.
Analysis of gelatinolytic activity
released in culture by different segments of atherosclerotic rabbit
aorta by SDS-PAGE zymography showed that the aortic arch
consistently produced the highest level of total
gelatinolytic activity. The activity released by
thoracic aorta was also higher than that of abdominal aorta (Figure 3
). The gradual increase in
gelatinolytic activity paralleled the extent of
macrophage-rich lesions. Migration of higher-molecular-weight
gelatinolytic activity was consistent with
the presence of MMP-9, whereas gelatinolytic
activity running at lower molecular weight was most likely due to
MMP-2, the main MMP produced by vascular SMCs. Analysis of
gelatinolytic activity released in culture by
isolated aortic or granulomatous FCs showed that these cells produce
copious amounts of the gelatinolytic activity
associated with MMP-9. Because gelatinolytic
profiles were identical for the FCs isolated from either source, we
used granuloma macrophages for further in vitro experiments.
Both lipid-laden and nonlipid-laden macrophages were
maintained in culture up to 5 days.

View larger version (99K):
[in a new window]
Figure 3. Detection of gelatinolytic
activity released by aortic segments and by isolated
macrophage-derived FCs. Gelatinolytic
activity released by abdominal aorta (Abd), thoracic aorta (Thr), and
aortic arch (Arch) was detected by SDS-PAGE zymography (white areas
indicate lysis of gelatin substrate, denoting presence of gelatinases).
Levels of total gelatinolytic activity, as well as
that of higher-molecular-weight activity indicative of MMP-9, were
consistently dependent on aortic region (Abd<Thr<Arch) and
paralleled extent of macrophage-rich lesions. The great
majority of gelatinolytic activity released in
culture by FCs isolated from aorta (aFC) and granuloma (gFC) run at
apparent molecular weight consistent with MMP-9. Same amount of
protein (20 µg) was loaded on each lane. Simultaneous
migration of prestained molecular weight markers (MWM) is indicated on
left in kilodaltons (kDa, kD).
Because our recent experiments showed that ROSs may function as
activators of SMC-derived latent
gelatinases,13 we hypothesized that activation of
FC-derived proMMP-9 may be related to concomitant production
of ROSs. To test ROS contribution, we treated macrophages with
NAC, an ROS scavenger. Gelatinolytic activity in
the culture media of untreated and NAC-treated cells was
analyzed by SDS-PAGE zymography. We found that 24 hours of
treatment with NAC reduced both the gelatinolytic
activity consistent with migration of the MMP-9 zymogen and
that of the faster band migrating at the expected position for active
MMP-9 (Figure 4
). To confirm the identity
of MMP-9 and to further assess effects of treatment, we also
analyzed the effect of NAC on MMP-9 protein level by
immunoblotting (Figure 5
). Comparing nonlipid-laden and
lipid-laden macrophages, we identified the MMP-9 precursor in
culture media conditioned by either macrophage population.
Interestingly, only the culture media conditioned by lipid-laden
macrophages contained the fully activated MMP-9,
migrating around 66 kDa as previously
reported.19 20 The same antiMMP-9 antibodies
did not recognize SMC-derived MMP-2, which has a similar apparent
molecular weight (not shown), confirming that this faster band was
indeed generated through processing of latent MMP-9. Culture media from
macrophage FCs treated with 10 mmol/L NAC for 48 hours had
significantly lower levels of the precursor and active forms of MMP-9.
NAC treatment also inhibited expression of the MMP-9 precursor by
nonlipid-laden macrophages. We also confirmed that the
decreased gelatinase production was not due to a cytotoxic
effect of NAC. Viability tests performed at the end of each experiment
showed that after 5 days in culture, FC viability was 79.3±6.8% live
cells in untreated versus 72.4±11.9% live cells treated with 10
mmol/L NAC (n=8, P=NS).

View larger version (31K):
[in a new window]
Figure 4. NAC reduces gelatinolytic
activity in culture media of macrophage-derived FCs. A,
SDS-PAGE gelatin zymography. Culture media were harvested from
macrophage FCs maintained in culture for up to 4 days in
absence (-) or presence (+) of 10 mmol/L NAC. Incubation of FCs
with NAC reduces gelatinolytic activity running at
both high apparent molecular weight (MW) and low MW. Migration of
gelatinolytic activity with high MW is
consistent with proMMP-9, while faster
gelatinolytic band is consistent with both
processed (active) form of MMP-9 and proMMP-2. B, Densitometric
analysis of gelatinolytic activity (high
and low MW) released by FCs shows a significant reduction after 48
hours of treatment with 10 mmol/L NAC. Values were normalized to
matched untreated control ±SEM (n=4 independent experiments,
*P<0.05).

View larger version (51K):
[in a new window]
Figure 5. NAC inhibits level of MMP-9 released by
macrophage-derived FCs. A, Western blotting. MMP-9 in cell
culture media was identified by monoclonal antibodies recognizing both
latent and active forms. FC culture media contain both forms, while
culture media of nonlipid-laden macrophages contain only
zymogen. MMP-9 signal is decreased in culture media of NAC-treated FCs.
B, NAC treatment decreases level of FC-derived proMMP-9 expression in
a dose-dependent fashion, as quantified by laser densitometry of
immunoblots. Graph represents data from 4
independent experiments in which FCs were incubated in presence of 1 or
10 mmol/L NAC for 48 hours. *P<0.05.
The results obtained with cultured macrophage-derived
FCs and nonlipid-laden macrophages suggested the possibility
of reducing production of active gelatinase by resident
macrophages through NAC treatment. This effect was tested by
incubating segments of atherosclerotic rabbit aorta with NAC in organ
culture conditions. We found that the NAC treatment abolished the
gelatinolytic activity released by aortic tissue
and significantly decreased the level of MMP-9 protein detected by
Western blotting (Figure 6
). The fact
that the effect of NAC was not restricted to inhibition of
gelatinolytic activity but rather also affected FC
MMP-9 expression was confirmed by the disappearance of MMP-9
immunopositive staining in the FC-rich lesions maintained in culture
with NAC (Figure 7
). This effect was
specific to the signal associated with the presence of MMP-9, since it
did not affect expression of macrophage markers also detected
by immunostaining. In addition, detection of MMP-9 was
not affected in paired untreated specimens that were maintained in
culture and processed simultaneously (Figure 7
). Thus, lack
of MMP-9 detection in lesions after treatment with NAC suggests that
the action of NAC is not restricted to inhibition of MMP-9 activity or
cellular secretion but rather also involves suppression of
macrophage MMP-9 synthesis.

View larger version (32K):
[in a new window]
Figure 6. NAC treatment abolishes
gelatinolytic activity and decreases MMP-9 protein
level released in vitro by aortic lesion explants. Aortic segments were
maintained in culture for up to 4 days with or without NAC. A,
Gelatinolytic activity released by tissue explants
of abdominal or thoracic aorta of hypercholesterolemic
rabbits in an experiment in which aortic explants were treated with
10 mmol/L for 24 hours (loading of all lanes was normalized by
protein). B, NAC treatment significantly diminished MMP-9 protein level
released by aortic explants, detected by immunoblotting
of culture media conditioned by segments of aortic arch, thoracic, and
abdominal atherosclerotic aorta. Tissues were incubated in presence (+)
or absence (-) of 10 mmol/L NAC for 24 hours. Bars
represent average values obtained by normalizing signal of
culture media conditioned by treated tissues to those of control
(untreated, -) specimens ±SEM in 4 independent experiments.
*P<0.05, **P<0.01.

View larger version (94K):
[in a new window]
Figure 7. NAC treatment reduces expression of MMP-9 in
rabbit atherosclerotic lesions. Atherosclerotic lesion specimens were
processed for immunodetection of macrophages and MMP-9 after
incubation in culture without or with NAC. Images illustrate segments
of abdominal aorta (top 2 panels), thoracic aorta (second 2 panels),
and aortic arch (bottom 4 panels) incubated for 48 hours with 10
mmol/L NAC. Top panels show that after NAC treatment, expression of
MMP-9 became undetectable in macrophage-derived FCrich
lesions. This effect was specific, because immunodetection of
macrophage markers (RAM-11) was not affected. Loss of MMP-9
signal was not due to maintaining tissues in culture, because MMP-9
immunostaining was not affected in matched untreated
segments of atherosclerotic aorta (bottom panels). Bar=100
µm.
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
Recently, the action of MMPs has emerged as an important component
of the natural history of
atherosclerosis8 11 21 and of the
vascular response to injury.22 23 24
Macrophage-derived FCs associate clinically with unstable
human plaques1 2 3 and microscopically with
vulnerable areas and active MMPs8 and thus may be
responsible for compromising vascular tissue integrity through matrix
degradation. Macrophages are also thought to be a major source
of the redox stress that characterizes atherosclerotic
vessels.25 26 27 In the present study, we
investigated production and activation of gelatinases produced
by macrophage FCs of hypercholesterolemic
rabbits, a good model for study of macrophage-derived FCs
resident in human atheroma. We also hypothesized that
macrophage-derived FCs have a built-in redox-dependent
mechanism leading to activation of their own MMP zymogens. We found
that gelatinolytic activity in rabbit
atherosclerotic lesions is restricted to the macrophage-rich
areas and colocalizes with expression of MMP-9. Study of isolated cells
confirmed that macrophage-derived FCs were a major source
of MMP-9 and detected the presence of active MMP-9. As mentioned,
increases in MMP-9 activity were previously reported in vascular
disease10 28 29 and a variety of other
pathological situations with an inflammatory component, such as
rheumatoid arthritis, as well as metastasis.30 To
obtain sufficient material for meaningful in vitro studies with
macrophage-derived FCs, we also induced formation of these
cells in vivo in granulomas of hypercholesterolemic
rabbits. Implantation of subcutaneous sponges triggers formation of
granulomas whose macrophages accumulate lipid in
hypercholesterolemic conditions. These
macrophage-derived FCs from subcutaneous granulomas had the
same MMP profile as the aortic FCs.
B, or SP-1responsive
elements.33 Conversely,
monocyte/macrophages constitutively express proMMP-9, but its
expression was shown to be enhanced by cellular
differentiation,7 concanavalin A, or LPS
stimulation.34 Interestingly, the effects of LPS,
cytokines, and phorbol esters may occur via generation of ROS
intermediates. In transformed cells, multiple pathways leading to
activation of redox-sensitive transcription
factors,35 such as NF-
B, SP-1, Ets, and AP-1,
have been shown to increase expression of
MMP-9.36 These additional considerations and the
present results support the hypothesis that MMP-9 gene expression
could be redox-regulated. As they become available, further experiments
using species-specific molecular probes will be performed to confirm
our observations at the messenger RNA level.
-tocopherol, peripheral blood monocytes
harvested from healthy volunteers produced fewer ROSs and interleukin-1
and displayed decreased adherence to endothelium when
stimulated with LPS.42 Also, NAC was found to
inhibit vascular cell adhesion molecule-1 expression in
vitro43 and in vivo.44
Abatement of these effects of oxidative stress in incipient stages of
atherosclerosis probably diminishes stimuli leading to
monocyte recruitment and formation of macrophage-derived
FCs. NAC was also found to inhibit the chemotactic and invasive
activities of human tumor cells, most likely through inhibition of
gelatinase activity,45 and it is currently
considered to be a promising antioxidant and anticancer chemopreventive
agent.32 Our study shows a new potential use for
NAC as an inhibitor of MMP activity. Inhibition of MMP
activity by antioxidants early in the course of atherosclerotic lesion
development may limit inflammatory cell infiltration, cell movement,
and proliferation, events that all require participation of active
MMPs. Importantly, by showing the possibility of inhibiting the
matrix-degrading capacity of macrophage FCs prevailing in
advanced plaques, the present results suggest that treatment with
ROS scavengers may be effective in late stages of
atherosclerosis. This would contribute to restricting
the weakening of vascular matrix, thought to be a major factor
precipitating plaque destabilization. Although we extensively examined
and report here the effects of NAC, we believe that the results are
applicable to other antioxidants, such as vitamin E and probucol, as
suggested by our preliminary experiments. Future in vivo experiments
need to be undertaken to confirm the possibility of using
antioxidant therapy as a way to improve the stability of
atherosclerotic plaques.
![]()
Selected Abbreviations and Acronyms
FC
=
foam cell
LPS
=
lipopolysaccharide
MMP
=
matrix metalloproteinase
MT-MMP
=
membrane-type MMP
NAC
=
N-acetyl-L-cysteine
NF
=
nuclear factor
ROS
=
reactive oxygen species
SMC
=
smooth muscle cell
![]()
Acknowledgments
This study was supported through funds provided by a
Grant-in-Aid from the American Heart Association and a faculty
development award from the Beda Whitaker Foundation.
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
This article has been cited by other articles:
![]() |
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakamura, M. Shibuya, H. Nakashima, R. Hisamura, N. Masuda, T. Imagawa, M. Uehara, and K. Tsubota Involvement of Oxidative Stress on Corneal Epithelial Alterations in a Blink-Suppressed Dry Eye Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1552 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Moon, S.-K. Kang, and C.-H. Kim Reactive oxygen species mediates disialoganglioside GD3-induced inhibition of ERK1/2 and matrix metalloproteinase-9 expression in vascular smooth muscle cells FASEB J, July 1, 2006; 20(9): 1387 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Perlstein and R. T. Lee Smoking, Metalloproteinases, and Vascular Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 250 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-N. Liu, S.-L. Pan, C.-Y. Peng, J.-H. Guh, D.-M. Huang, Y.-L. Chang, C.-H. Lin, H.-C. Pai, S.-C. Kuo, F.-Y. Lee, et al. YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] Inhibits Neointima Formation in Balloon-Injured Rat Carotid through Suppression of Expressions and Activities of Matrix Metalloproteinases 2 and 9 J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1903 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. El Bedoui, M.-H. Oak, P. Anglard, and V. B. Schini-Kerth Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression Cardiovasc Res, August 1, 2005; 67(2): 317 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Oak, J. El Bedoui, P. Anglard, and V. B. Schini-Kerth Red Wine Polyphenolic Compounds Strongly Inhibit Pro-Matrix Metalloproteinase-2 Expression and Its Activation in Response to Thrombin via Direct Inhibition of Membrane Type 1-Matrix Metalloproteinase in Vascular Smooth Muscle Cells Circulation, September 28, 2004; 110(13): 1861 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Wyche, S. S. Wang, K. K. Griendling, S. I. Dikalov, H. Austin, S. Rao, B. Fink, D. G. Harrison, and A. M. Zafari C242T CYBA Polymorphism of the NADPH Oxidase Is Associated With Reduced Respiratory Burst in Human Neutrophils Hypertension, June 1, 2004; 43(6): 1246 - 1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Griendling and G. A. FitzGerald Oxidative Stress and Cardiovascular Injury: Part II: Animal and Human Studies Circulation, October 28, 2003; 108(17): 2034 - 2040. [Full Text] [PDF] |
||||
![]() |
M. Girndt and H. Kohler Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1976 - 1979. [Full Text] [PDF] |
||||
![]() |
M. Lappas, M. Permezel, and G. E. Rice N-Acetyl-Cysteine Inhibits Phospholipid Metabolism, Proinflammatory Cytokine Release, Protease Activity, and Nuclear Factor-{kappa}B Deoxyribonucleic Acid-Binding Activity in Human Fetal Membranes in Vitro J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1723 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Allen, D. H. Teitelbaum, and K. Kurachi Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro Am J Physiol Cell Physiol, April 1, 2003; 284(4): C805 - C815. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z S Nedeljkovic, N Gokce, and J Loscalzo Mechanisms of oxidative stress and vascular dysfunction Postgrad. Med. J., April 1, 2003; 79(930): 195 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Sampson, N. Gopaul, I. R. Davies, D. A. Hughes, and M. J. Carrier Plasma F2 Isoprostanes: Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes Diabetes Care, March 1, 2002; 25(3): 537 - 541. [Abst |